JPMorgan reinstated coverage of Insmed with an Overweight rating and $36 price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSM:
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Insmed price target raised to $35 from $33 at Mizuho
- Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
- Insmed reports Q3 EPS ($1.11), consensus ($1.12)
- Insmed and Google Cloud partner for AI use in drug development
